C Ray Therapeutics Secures $100M in Series A+ Financing

Imagine building something from scratch in just three years—something so groundbreaking that investors throw $100 million at you, betting it could change medicine forever.

That’s not a movie script; it’s the real story of C Ray Therapeutics, a radiopharmaceutical trailblazer out of Chengdu, China.

In a world where cutting-edge cancer therapies are the holy grail of medicine, C Ray has quietly but swiftly emerged as a serious contender.

The company recently closed a $100 million Series A+ funding round, spearheaded by heavyweights like Shenzhen Capital Group (SCGC) and TaiLong Capital, with big names like GL Ventures and 3SBio also in the mix.

This isn't your average startup success story. Founded in 2021, C Ray has already achieved what some companies take decades to do.

From establishing a state-of-the-art 30,000-square-meter facility in Chengdu Medical City to securing the elusive Class A Radiation Safety License, it’s clear the team isn’t here to play—they’re here to transform healthcare.

If you’re not familiar with radiopharmaceuticals, think of them as the superheroes of modern medicine. These drugs don’t just target diseases like cancer—they light them up, making diagnostics more precise and treatments more effective. It’s like GPS-guided missiles for your body, but in a good way.

C Ray is tackling this high-stakes game with a full-spectrum approach, handling everything from sourcing isotopes to producing patient-ready treatments.

They’re not just making the drugs; they’re building the infrastructure and expertise to lead a revolution in this space.

Why $100M?

So, why are investors throwing money at C Ray like it’s the next big tech startup?

According to SCGC, “High-end drug carriers are pivotal to the future of global biomedical development.” Simply put, radiopharmaceuticals are no longer niche—they’re the next frontier.

The funding will supercharge C Ray’s research into Radionuclide Drug Conjugates (RDCs), particularly alpha-emitting therapies that promise to be game-changers in cancer treatment. The company’s R&D platform is designed to handle more than 30 medical isotopes, ensuring global scalability.

But it’s not just about the science. C Ray is also offering a one-stop-shop model, allowing partners to use its advanced facilities for their own projects. It’s collaboration meets innovation, and investors are loving it.

This funding round is more than just a financial milestone. It’s a statement that C Ray is ready to go global.

Local governments in Chengdu see the company as a cornerstone of their push to make the city a hub for radiopharmaceutical innovation.

Meanwhile, industry experts are keeping a close eye. GL Ventures calls C Ray a “key integrator of the nuclear medicine supply chain,” while TaiLong Capital sees its holistic approach as the secret sauce that sets it apart.

As the race to innovate in cancer treatment heats up, C Ray Therapeutics isn’t just participating—it’s leading.

The road ahead is ambitious, but if the past three years are anything to go by, we’re looking at a company poised to make history.